Trial Profile
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC-4; PACIFIC-4/RTOG-3515
- Sponsors AstraZeneca; AstraZeneca AB
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 The protocol was amended to exclude patients with an identified EGFRm from the main cohort and add a separate cohort of approximately 60 patients with EGFRm (L858R or Ex19del) who will receive osimertinib 80 mg PO QD, following SoC SBRT, for up to 36 months.
- 25 May 2023 According to an AstraZeneca media release, trials-in-progress data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.